NEW YORK, October 22, 2018 /PRNewswire/ --
According to Grand View Research, the global biotechnology market is expected to reach USD 727.1
billion by 2025. The emergence of certain key factors in the biotechnology market is expected to drive the strong growth.
These key factors include regenerative medicine and genetics in diagnostics, various developments in cancer therapeutics, as well
as advances made in the treatment of common diseases such as Multiple Sclerosis and Alzheimer's. Innovative companies in the
industry are engaged in large clinical trials and strong R&D investments for cancer therapeutics, as oncology is one of the
most promising areas of focus in the biotech industry. Cognetivity Neurosciences Ltd. (OTC: CGNSF), Amgen Inc. (NASDAQ: AMGN),
Allergan plc (NYSE: AGN), Stryker Corporation (NYSE: SYK), Varian Medical Systems, Inc. (NYSE: VAR)
"Rising incidence of oncology diseases is anticipated to drive the demand for next-generation cancer diagnostic tests. These
tests are expected to facilitate early diagnosis and enable efficient prognosis of various forms of cancer, which in turn, is
expected to positively influence progress of this vertical over the forecast period. Development and introduction of product
offerings by a number of large entities is a significant factor expected to provide lucrative growth avenues to this market,
active participation of global organizations, such as National Cancer Institute, Cancer Research Institute, National Foundation
for Cancer Research, and Cancer Research UK, are supportive of the projected sector progress," GVR reports.
Cognetivity Neurosciences Ltd. (OTCQB: CGNSF) is also listed on the Canadian Securities Exchange under the ticker (CSE:
CGN). Earlier this month the company announced news that, it has been selected to present landmark results from its ongoing
research into the use of the company's Integrated Cognitive Assessment in the detection of early stage cognitive impairment
associated with Multiple Sclerosis at the 34th congress of the European Committee For Treatment and Research In Multiple
Sclerosis (MS) (ECTRIMS), held in Berlin, Germany.
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a non-profit organisation and an
independent representative European-wide organisation devoted to Multiple Sclerosis. ECTRIMS works with researchers and
clinicians of its member countries and with other organisations that share similar missions and objectives on a worldwide scale,
creating networking and collaboration opportunities. In a talk titled 'A brief language-independent and self-administered
computerized test for cognitive assessment in multiple sclerosis (MS)', Cognetivity's Chief Scientific Officer, Dr. Seyed-Mahdi Khaligh-Razavi will present an overview of the company's unique AI-based approach, and deliver
positive results from ongoing trials into the effectiveness of its proprietary Integrated Cognitive Assessment (ICA) platform for
early detection of cognitive impairment in populations of Multiple Sclerosis patients.
The results that will be included in the presentation are as follows:
- Details on the ICA, a five-minute test delivered via Apple iPads, the results from which are unaffected by culture,
language and education, and which can be carried out unsupervised, meaning there is no need for health professionals to
administer, a high cost factor with existing tests;
- Data demonstrating the ICA's excellent consitency for repeated testing and high level of convergent validity with the
highly sensitive and expert-administered BICAMS battery of cognitive tests;
- Data demonstrating the ICA test's ability to discriminate between MS patients and healthy control subjects;
- Data demonstrating the ICA's high level of accuracy in discriminating cognitively normal from cognitively impaired
participants; and
- Data demonstrating that the ICA test showed no learning bias, making it suitable for frequent monitoring of cognitive
performance.
Select attendees of the meeting include leading global pharmaceutical companies Merck, Novartis, Roche and Sanofi and leading
academics from the field of MS research from institutions such as Cambridge University, Harvard Medical School, Massachussetts General Hospital, University College London and UCSF.
Cognetivity's CEO, Dr Sina Habibi said: "We are very excited that our Chief Scientific Officer,
Dr. Khaligh-Razavi, is presenting these results at the ECTRiMS meeting, a very prestigious MS conference. What is particularly
important is that we are able to demonstrate that our ICA platform can be used in other disease areas over and above our
excellent, research-backed capability in Alzheimer's disease and mild cognitive impairment (MCI). The fact that the ICA is able
to detect the early signs of cognitive impairment associated with MS and that it performs very well compared with a highly
sensitive, time consuming, expert-administered cognitive test demonstrates its effectiveness in a number of disease areas. The
advantages of our platform in terms of sensitivity, usability, administration cost and repeatability over existing testing
methods are clear and, based on those factors, we believe our technology has an important role to play in the future of cognitive
testing in a growing number of major disease areas."
Cognitive impairment is increasingly recognized to be a core feature of MS, with important implications for the everyday life
of individuals with MS and for disease management. There are an estimated 2.3 million sufferers worldwide and the global
therapeutics market for MS estimated to reach US $24.8 billion by 2024. Early detection of
cognitive impairment in MS is an important aspect of the clinical appraisal of sufferers, as its presence has a negative
influence on physical independence and competence in daily activities and currently, cognitive testing involves time-consuming,
expert administered pen and paper tests. There is a widely recognized and urgent need for an easy to administer test with the
ability to reliably detect and regularly monitor cognitive ability in MS patients in order to allow clinicians to direct the most
effective treatment to sufferers.
About Cognetivity Neurosciences Ltd. - Cognetivity is a technology company developing a cognitive testing platform, the
Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial
Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large
areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned
clinical studies to the market in North America and Europe.
For more information please visit - http://www.cognetivity.com
Amgen Inc. (NASDAQ: AMGN) is committed to unlocking the potential of biology for patients suffering from serious
illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen recently announced the
groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West
Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation
biomanufacturing capabilities to manufacture products for the U.S. and global markets. A next-generation biomanufacturing plant
incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with
approximately one half of the operating cost of a traditional plant. Next-generation biomanufacturing plants require a smaller
manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower
levels of carbon emissions. Within the plant, the equipment is portable, smaller and some components are disposable, which
provides greater flexibility and speed when manufacturing different medicines simultaneously. This eliminates costly and complex
retrofitting inherent in standard facilities and allows Amgen to respond to changing demands for its medicines with increased
agility, ultimately impacting the speed at which a medicine is available for patients. "Biologics manufacturing is a complex
science and has long been a competitive advantage for Amgen," said Robert A. Bradway, Chairman and
Chief Executive Officer at Amgen. "We are working to extend that advantage even further with a next-generation biomanufacturing
plant in Rhode Island that will produce medicines to serve patients around the world suffering
from serious illnesses."
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical leader. Allergan plc recently announced the completion of two positive safety and tolerability studies of
ubrogepant for the acute treatment of migraine. The first study (UBR-MD-04) evaluated the long-term safety and tolerability of
ubrogepant (50 mg and 100 mg) compared to usual care for the acute treatment of migraine in adults for one year. The second study
(3110-105-002) evaluated the hepatic safety and tolerability of ubrogepant 100 mg compared to placebo in healthy study
participants over eight weeks. Based on the completion of these safety studies for ubrogepant and previously reported efficacy
and safety results from the ubrogepant ACHIEVE I (UBR-MD-01) and ACHIEVE II (UBR-MD-02) studies, Allergan will submit a New
Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the first quarter of 2019. Allergan anticipates that the
ubrogepant NDA will be the first oral CGRP receptor antagonist submitted in the U.S. for the acute treatment of migraine with or
without aura. "Allergan remains at the forefront of addressing unmet patient needs among migraine patients by developing new and
innovative treatment options," said David Nicholson, Chief Research and Development Officer,
Allergan. "We are pleased with the positive results from these two important studies supporting the safety and tolerability of
ubrogepant and look forward to filing the NDA for this promising treatment option for adults living with migraine."
Stryker Corporation (NYSE: SYK) is one of the world's leading medical technology companies and, together with its
customers, is driven to make healthcare better. Stryker recently announced the acquisition of privately-held HyperBranch Medical
Technology, Inc. for a total equity value of approximately USD 220 Million in an all cash
transaction. HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels.
Its Adherus AutoSpray Dural Sealant product is one of only two FDA-approved dural sealants on the market. As a PMA approved and
CE cleared hydrogel that is indicated for use as an adjunct to standard methods of dural repair to aid in creating a watertight
closure of the dura, the Adherus product is highly complementary to Stryker's Craniomaxillofacial division. The patent protected
sealant formulation, combined with a differentiated delivery system, is proven through clinical trials to provide clinically safe
and effective dural closure. "The acquisition of HyperBranch supports our growth strategy within our Neurotechnology business,"
said Spencer S. Stiles, Group President, Neurotechnology, Instruments and Spine for Stryker. "The
addition of Adherus to our cranial closure portfolio strengthens our position of excellence in the dural repair space and aligns
with Stryker's mission of making healthcare better."
Varian Medical Systems, Inc. (NYSE: VAR) is a leader in developing and delivering cancer care solutions and is focused
on creating a world without fear of cancer. Varian recently announced the acquisition of privately-held software company Noona
Healthcare, developer of a cloud-based, mobile service designed to capture cancer patient-reported outcomes (PROs). The Noona
patient software app lets clinics capture PROs and communicate directly with patients. This acquisition expands Varian's
portfolio of cancer care solutions and fits the company's long-term growth and value creation strategy. Noona's intuitive user
interface creates an engaging experience for patients that encourages a high rate of adoption and adherence over long periods.
Noona helps patients and care teams to proactively manage patient symptoms, which could lead to improved clinical outcomes and
reduced hospitalization and emergency room visits. "We are excited to add the Noona technology and team to Varian as we continue
to become a global leader in multi-disciplinary integrated cancer care solutions, focused on improving patient care," said
Corey Zankowski, senior vice president, Oncology Software Solutions, Varian. "This acquisition
adds smart mobile technology to Varian's cloud-based software portfolio. It will allow oncologists to capture real-time PROs and
monitor and proactively manage their patient's symptoms. Sustained engagement with patients may help oncologists detect early
signs of potential recurrence or progression of metastatic disease."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For cognetivity neurosciences ltd. financial and corporate news dissemination,
FinancialBuzz.com expects to be compensated four thousand dollars by winning media. Our fees may be
either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination
thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on
or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments
for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site
or continue to post information about any companies the information contained herein is not intended to be used as the basis for
investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is
not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for
any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other
materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of
their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance,
and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound
by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed.
For our full disclaimer, disclosure and Terms of Use, please visit:http://www.financialbuzz.com
For further information:
Media Contact: info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com